[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"childhood-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:childhood-leukemia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100399194","advanced-translational-research-on-childhood-leukemia-100399194",false,"NCT04478006","Advanced Translational Research on Childhood Leukemia","Driving Therapeutic Progress of Childhood Leukemia Through Advanced Translational Research With Immediate and Long-term Impact. Precision Medicine for Childhood Leukemia.","List of inclusion criteria:\n\n1. acute lymphoblastic leukemia (ALL) or\n2. acute myeloid leukemia (AML) or\n\n3 .mixed phenotype acute leukemia (MPAL) or\n\n4\\. juvenile myelomonocytic leukemia (JMML) or\n\n5\\. myelodysplastic syndromes (MDS) or\n\n6\\. normal bone marrow donor\n\nList of exclusion criteria:\n\n1. This study will not recruit subjects who are unable to understand English or Chinese.\n2. Patient or parent refusal",true,"ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","Prognosis of children with leukemia, the most common pediatric cancer, has improved markedly. Yet, relapse still occurs in 15-40% of patients with a probability of survival of \\\u003C50%, which is unlikely to be boosted by intensification of standard chemotherapy due to overwhelming toxicity. The advent of effective and safe targeted therapies for high-risk cases is therefore imperative. This study constitutes two research projects aiming at driving therapeutic advances.",[25],"Childhood Leukemia","RECRUITING","2026-02-01",{"date":29,"type":30},"2026-02-03","ACTUAL",{"date":32,"type":30},"2020-07-01",{"date":34,"type":21},"2028-06-01",{"name":36,"class":37},"Chinese University of Hong Kong","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":57,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100478038","precision-medicine-for-every-child-with-cancer-100478038","NCT05504772","Precision Medicine for Every Child With Cancer","ZERO2","Inclusion Criteria:\n\n1. Age \\\u003C 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate.\n2. Life expectancy \\>6 weeks at time of enrolment\n3. Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent\u002Fguardian of participant aged \\\u003C18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.","0 Years","25 Years",{"count":49,"type":21},3500,"To improve outcomes for childhood cancer patients through the implementation of precision medicine.",[52,53,54,25,55,56],"Childhood Cancer","Childhood Solid Tumor","Childhood Brain Tumor","Refractory Cancer","Relapsed Cancer",[58,59,60,61,62,63],"children","precision medicine","personalised medicine","molecular profiling","pediatric","paediatric","2024-07-16",{"date":66,"type":30},"2024-07-17",{"date":68,"type":30},"2022-12-16",{"date":70,"type":21},"2030-07",{"name":72,"class":37},"Australian & New Zealand Children's Haematology\u002FOncology Group",11]